Within novel diagnostics tests, needing clinical utility evidence cannot be understated. And the more evidence accumulated over years, the better. But why? Today’s guest is Dr. Virginia Calega, the President of VCC Healthcare Solutions, and she makes a highly compelling argument that, if payors are going to accept a new novel diagnostic test, and disrupt what they already have, it has to be backed by substantial evidence. Join us as we also discuss: The contrary belief of expensive tests CAN be approved by payorsThe need to clearly define the novel test for the patient’s clinical journeyThe ultimate savings cost built into the newer tests-----------------------------------------------Stay connected with our host, Perry Dimas, here on LinkedIn! 

Ver todos los episodios